TD-HW541026

Inbakicept(TD-HW541026) is a research-grade recombinant antibody targetingIL15. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Functional assay, Research in vivo

Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL-15RA)]2 - IGHG1 Fc (Fragment constant)

IL15, IL-15, Interleukin-15

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P40933

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

ALT-803(=inbakiceptINN11029([IL15RA]2-Fc)incomplex1:2withnogapendekinalfaINN11157(IL15D72)), [IL15RA]2-Fc, 2135939-52-3

Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells.• Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer., PMID:35660135• Interleukin 15: A key cytokine for immunotherapy., PMID:27325459• IL-15 in the Combination Immunotherapy of Cancer., PMID:32508818• IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells., PMID:31277710• Interleukin-15 in autoimmunity., PMID:32919253• Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers., PMID:39604730• An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery., PMID:36165896• IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease., PMID:32051586• Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effectin vivo., PMID:37818365• Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy., PMID:34797911

SDS-PAGE for Research Grade Inbakicept

For research use only. Not suitable for clinical or therapeutic use.